Andere Kunden interessierten sich auch für
![Cutaneous Oncology and Dermatologic Surgery, an Issue of Dermatologic Clinics]( "Cutaneous Oncology and Dermatologic Surgery, an Issue of Dermatologic Clinics")
Cutaneous Oncology and Dermatologic Surgery, an Issue of Dermatologic Clinics130,99 €![Non-Invasive Technologies for the Diagnosis and Management of Skin Cancer, an Issue of Dermatologic Clinics]( "Non-Invasive Technologies for the Diagnosis and Management of Skin Cancer, an Issue of Dermatologic Clinics")
Non-Invasive Technologies for the Diagnosis and Management of Skin Cancer, an Issue of Dermatologic Clinics130,99 €![Cutaneous Oncology Update, An Issue of Dermatologic Clinics]( "Cutaneous Oncology Update, An Issue of Dermatologic Clinics")
Cutaneous Oncology Update, An Issue of Dermatologic Clinics109,99 €![The Intersection of Dermatology and Oncology, an Issue of Dermatologic Clinics]( "The Intersection of Dermatology and Oncology, an Issue of Dermatologic Clinics")
The Intersection of Dermatology and Oncology, an Issue of Dermatologic Clinics130,99 €![Confocal Microscopy, an Issue of Dermatologic Clinics]( "Confocal Microscopy, an Issue of Dermatologic Clinics")
Confocal Microscopy, an Issue of Dermatologic Clinics130,99 €![Advances in Acne Management, an Issue of Dermatologic Clinics]( "Advances in Acne Management, an Issue of Dermatologic Clinics")
Advances in Acne Management, an Issue of Dermatologic Clinics118,99 €![Vitiligo, an Issue of Dermatologic Clinics]( "Vitiligo, an Issue of Dermatologic Clinics")
Vitiligo, an Issue of Dermatologic Clinics130,99 €
The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists.
Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.